ReviewFrontiers in immunology2026
TSPO in systemic-ocular immunometabolic crosstalk: mechanisms and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eye is increasingly recognized as a tissue shaped by systemic immune and metabolic states rather than an isolated immune-privileged organ. Translocator protein (TSPO), an 18-kDa outer mitochondrial membrane protein enriched in myeloid and glial cells, links mitochondrial homeostasis, redox signaling, lipid metabolism, and immune polarization. This review synthesizes evidence for TSPO involvement in systemic-ocular immunometabolic crosstalk and organizes it into a three-stage working model: peripheral immunometabolic priming, blood-retinal barrier vulnerability, and intraocular glial amplification. We review evidence from systemic autoimmune diseases with ocular manifestations, metabolic diseases with ocular complications, and primary ocular diseases with systemic contributions. We then assess the potential of TSPO as an imaging or fluid biomarker and as a therapeutic target. Current evidence suggests that TSPO is a promising immunometabolic node and underscores the need for cross-organ disease models, cell-specific TSPO manipulation, spatial multi-omics, and local ocular delivery strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.